Search

Displaying results 781 - 790 of 4339 in total
  1. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    Segesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.

  2. Drug

    Sparfloxacin

    go.drugbank.com/drugs/DB01208
    ApprovedWithdrawn

    Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.

  3. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940] … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.

  4. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]

  5. Drug

    Montelukast

    go.drugbank.com/drugs/DB00471
    ApprovedInvestigational

    Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.

    Products: XALAR 10MG., SINGULAIR 10MG
  6. Drug

    Cyanocobalamin

    go.drugbank.com/drugs/DB00115
    ApprovedInvestigationalNutraceutical

    This drug was initially approved by the FDA in 1942 [FDA label]. … This vitamin is produced naturally by bacteria [A175276], and is necessary for DNA synthesis and cellular energy production.

    Mixtures: B Complex With C 300mg, B Complex Plus C 300mg Tab
  7. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … DTPA, along with its calcium and zinc trisodium salts, are the only FDA approved agents for the treatment of internal contamination by transuranics.

  8. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. … By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.

    Products: Jakavi 20mg Tablets, Jakavi 10mg Tablets
  9. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. … [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.

  10. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.